

Prof. Nikolaos Perakakis, MD

1 | General information

Contact details: Department of Medicine III, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
Fetscherstr. 74, 01307 Dresden, Germany

Tel.: +49 (0)351 458-13651

E-mail: Nikolaos.Perakakis@uniklinikum-dresden.de



Current position: Professor of Metabolic and Vascular Medicine (W2), Head of Section of Metabolic Vascular Medicine, Director of Clinical Research Center for Metabolic Diseases, Department of Medicine III, Technische Universität Dresden, Germany

Researcher unique identifier(s): ORCID-ID: 0000-0002-2319-6603

2 | Academic education

2018 – 2019 DFG Postdoctoral research Fellowship, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
2000 – 2006 Medical School, University of Athens, Greece
1999 – 2000 Veterinary Medicine, Aristotle University of Thessaloniki, Greece

3 | Advanced academic qualifications:

2013 MD thesis (*summa cum laude*), Endocrinology and Diabetology, “*The role of the zinc-finger transcription factor Krüppel-like factor 11 for gene regulation in pancreatic beta cells*”, Medical School of Freiburg (Supervisor: Jochen Seufert)

4 | Postgraduate professional career:

Since 2021 Head of Section of Metabolic Vascular Medicine, and Director of Clinical Research Center for Metabolic Diseases, Department of Medicine III, Technische Universität Dresden, Germany
Since 2021 Research Collaborator, Beth Israel Deaconess Medical Center, Harvard University, Boston, USA
2021 W2 Professor of Metabolic and Vascular Medicine, TU Dresden
2021 Higher Education Teaching Certificate, Harvard University, The Derek Bok Center for Teaching and Learning
2019 – 2021 Instructor of Medicine, Harvard Medical School, Boston, USA
2018 DFG Postdoctoral research Fellowship, “7M-Multiomic Multiscale and Multifidelity Modeling via Machine Learning: Application to Diagnosis and to Macrovascular and Microvascular complications in NAFLD”
2016 – 2019 Postdoctoral research fellow, Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School, Boston, USA
2015 – 2016 Consultant in Internal Medicine, Endocrinology and Diabetology, University Hospital of Freiburg, Germany
2015 German board certification *Internal Medicine, Endocrinology and Diabetology*
2008 – 2015 Resident and Fellow in Internal Medicine, Endocrinology and Diabetology, University Hospital of Freiburg, Germany
2006 – 2008 Scientific assistant, Internal Medicine, Endocrinology and Diabetology, University Hospital of Freiburg, Germany

5 | Other:

Awards/Honors

- Funding award from German Diabetes Society (DDG) (2021)
- Reintegration Fellowship of DFG (2020)
- Funding award from German Diabetes Society (DDG) (2015)
- Member of the group of “Rising Stars” in Diabetes, Sanofi Aventis (2014)
- Young Endocrinologist Award of the German Society of Endocrinology (2011)

Other professional activities:

- Member of the Clinical Study Board of Deutsches Zentrum für Diabetesforschung (DZD)
- Editorial board: Metabolism, World Journal of Diabetes, PLOS one, BMC Endocrine Disorders, Data in Brief
- Ad-hoc peer reviewer for 3 European universities/foundations: University of Foro Italico (Rome, Italy), University of Mons (Mons, Belgium), Austrian Science Fund (FWF)

6 | Selected publications:

1. **Perakakis N**, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. **Int J Mol Sci** 2021; 22(12):6332
2. **Perakakis N**, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. **Liver Int** 2021; 41(8):1853-66
3. **Perakakis N**, Farr OM, Mantzoros CS. Leptin in Leanness and Obesity: JACC State-of-the-Art Review. **J Am Coll Cardiol** 2021; 77(6):745-60
4. **Perakakis N**, Farr OM, Mantzoros CS. Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward- and attention-related brain centres in response to visual food cues in adults with obesity: A cross-sectional functional MRI study. **Diabetes Obes Metab** 2021; 23(5):1202-7
5. Chrysafi P*, **Perakakis N***, Farr OM, Stefanakis K, Peradze N, Sala-Vila A, Mantzoros CS. Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. **Nat Commun** 2020; 11(1):5145
6. **Perakakis N**, Joshi A, Peradze N, Stefanakis K, Li G, Feigh M, Veidal SS, Rosen G, Fleming M, Mantzoros CS. The selective peroxisome proliferator-activated receptor gamma modulator CHS-131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis. **Hepatol Commun** 2020; 4(9):1302-15
7. **Perakakis N***, Polyzos SA*, Yazdani A*, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. **Metabolism** 2019; 101:154005
8. Polyzos SA*, **Perakakis N***, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. **J Clin Endocrinol Metab** 2020; 105(3)
9. **Perakakis N***, Kokkinos A*, Peradze N, Tentolouris N, Ghaly W, Tsilingiris D, Alexandrou A, Mantzoros CS. Follistatins in glucose regulation in healthy and obese individuals. **Diabetes Obes Metab** 2019;21(3): 683-690
10. **Perakakis N**, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. **Nat Rev Endocrinol** 2017;13(6):324-337

*contributed equally

Patents:

1. **Perakakis N**, Mantzoros C, Yazdani A. Diagnosis and treatment of NAFLD and liver fibrosis (applied). International Publication Number for Patents WO 2021/092265A1